Form 4: Gilead Sciences Increases Stake in Xilio Therapeutics Through Stock and Warrant Purchase

Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its beneficial ownership through the acquisition of common stock and prefunded warrants.

Summary

• On April 2, 2024, Gilead Sciences acquired 485,250 shares of Xilio Therapeutics common stock at a price of $0.76 per share.
• Additionally, Gilead Sciences purchased 3,882,450 prefunded warrants with an exercise price of $0.0001, each warrant entitling them to purchase one share of common stock at $0.7599.
• Following these transactions, Gilead Sciences directly owns 7,345,473 shares of common stock and 3,882,450 prefunded warrants.
• The prefunded warrants are immediately exercisable but are subject to a 19.99% ownership limitation based on Section 13(d) of the Securities Exchange Act of 1934.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to Gilead's increased investment, suggesting confidence in Xilio's future. However, the ownership limitations on the warrants introduce a degree of caution.

Positives

• Gilead Sciences' increased investment signals confidence in Xilio Therapeutics' prospects.
• The immediate exercisability of the prefunded warrants provides Xilio Therapeutics with potential future capital.

Risks

• The 19.99% ownership limitation on the prefunded warrants could restrict Gilead Sciences' ability to fully exercise its warrants.
• The exercise of the warrants is dependent on Gilead Sciences' overall ownership position and compliance with securities regulations.

Future Outlook

The document does not explicitly provide a future outlook, but the increased investment by Gilead Sciences suggests a positive view of Xilio Therapeutics' potential.

Industry Context

This announcement reflects ongoing investment activity within the biotechnology sector, where larger pharmaceutical companies often take strategic stakes in smaller, innovative firms like Xilio Therapeutics.

Comparison to Industry Standards

• Gilead's investment in Xilio is similar to other strategic investments made by large pharmaceutical companies in smaller biotechs with promising technologies.
• Companies like Roche, Novartis, and Pfizer frequently make similar investments to gain access to novel therapies and technologies.
• The size of the investment is within the typical range for such deals, but the specific terms (prefunded warrants) can vary based on the specific circumstances and negotiation between the parties.

Stakeholder Impact

• Shareholders of Xilio Therapeutics may view Gilead Sciences' increased investment positively.
• The potential capital injection from warrant exercises could benefit Xilio's operations and research.

Key Dates